Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease
Identifieur interne : 000E85 ( Main/Corpus ); précédent : 000E84; suivant : 000E86Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease
Auteurs : M. SteigerSource :
- European Journal of Neurology [ 1351-5101 ] ; 2008-01.
English descriptors
- KwdEn :
Abstract
Current dopaminergic therapies for the treatment of Parkinson's disease are associated with the development of long‐term motor complications. Abnormal pulsatile stimulation of dopamine receptors is thought to underlie the development of motor complications. There is thus a need for therapies that mimic the normal physiological state more closely by resulting in constant dopaminergic stimulation (CDS). Several studies support the hypothesis that CDS can reverse levodopa‐induced motor complications. Other potential benefits of CDS include alleviating nocturnal disturbances, minimizing daytime sleepiness, avoiding priming for motor fluctuations and dyskinesia, preventing the development of gastrointestinal dysfunction and reducing the risk of developing psychosis or behavioural disturbances. Continuous infusion of dopaminergic therapies is impractical for the routine treatment of large numbers of patients. Although catechol‐O‐methyltransferase inhibitors or sustained‐release preparations of levodopa may be beneficial, they do not entirely eliminate pulsatile stimulation of dopamine receptors. A new dopamine agonist (rotigotine), delivered over 24 h by a once‐daily transdermal patch, has been investigated in several clinical trials. Continuous delivery of rotigotine has been shown to provide ‘true’ CDS in animal models. The potential of true CDS therapy to prevent or reduce long‐term motor and non‐motor complications requires investigation in appropriately designed clinical trials.
Url:
DOI: 10.1111/j.1468-1331.2007.01674.x
Links to Exploration step
ISTEX:79DB4C9C3D025C0A3FD2EB3451F445BDF602CBEALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease</title><author><name sortKey="Steiger, M" sort="Steiger, M" uniqKey="Steiger M" first="M." last="Steiger">M. Steiger</name><affiliation><mods:affiliation>Walton Centre for Neurology and Neurosurgery, NHS Trust, Liverpool, UK</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:79DB4C9C3D025C0A3FD2EB3451F445BDF602CBEA</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1111/j.1468-1331.2007.01674.x</idno><idno type="url">https://api.istex.fr/document/79DB4C9C3D025C0A3FD2EB3451F445BDF602CBEA/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000E85</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease</title><author><name sortKey="Steiger, M" sort="Steiger, M" uniqKey="Steiger M" first="M." last="Steiger">M. Steiger</name><affiliation><mods:affiliation>Walton Centre for Neurology and Neurosurgery, NHS Trust, Liverpool, UK</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Neurology</title><idno type="ISSN">1351-5101</idno><idno type="eISSN">1468-1331</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2008-01">2008-01</date><biblScope unit="volume">15</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="6">6</biblScope><biblScope unit="page" to="15">15</biblScope></imprint><idno type="ISSN">1351-5101</idno></series><idno type="istex">79DB4C9C3D025C0A3FD2EB3451F445BDF602CBEA</idno><idno type="DOI">10.1111/j.1468-1331.2007.01674.x</idno><idno type="ArticleID">ENE1674</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1351-5101</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>constant dopaminergic stimulation</term><term>dopaminergic</term><term>rotigotine</term><term>transdermal</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Current dopaminergic therapies for the treatment of Parkinson's disease are associated with the development of long‐term motor complications. Abnormal pulsatile stimulation of dopamine receptors is thought to underlie the development of motor complications. There is thus a need for therapies that mimic the normal physiological state more closely by resulting in constant dopaminergic stimulation (CDS). Several studies support the hypothesis that CDS can reverse levodopa‐induced motor complications. Other potential benefits of CDS include alleviating nocturnal disturbances, minimizing daytime sleepiness, avoiding priming for motor fluctuations and dyskinesia, preventing the development of gastrointestinal dysfunction and reducing the risk of developing psychosis or behavioural disturbances. Continuous infusion of dopaminergic therapies is impractical for the routine treatment of large numbers of patients. Although catechol‐O‐methyltransferase inhibitors or sustained‐release preparations of levodopa may be beneficial, they do not entirely eliminate pulsatile stimulation of dopamine receptors. A new dopamine agonist (rotigotine), delivered over 24 h by a once‐daily transdermal patch, has been investigated in several clinical trials. Continuous delivery of rotigotine has been shown to provide ‘true’ CDS in animal models. The potential of true CDS therapy to prevent or reduce long‐term motor and non‐motor complications requires investigation in appropriately designed clinical trials.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>M. Steiger</name><affiliations><json:string>Walton Centre for Neurology and Neurosurgery, NHS Trust, Liverpool, UK</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>constant dopaminergic stimulation</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dopaminergic</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>rotigotine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>transdermal</value></json:item></subject><articleId><json:string>ENE1674</json:string></articleId><language><json:string>eng</json:string></language><abstract>Current dopaminergic therapies for the treatment of Parkinson's disease are associated with the development of long‐term motor complications. Abnormal pulsatile stimulation of dopamine receptors is thought to underlie the development of motor complications. There is thus a need for therapies that mimic the normal physiological state more closely by resulting in constant dopaminergic stimulation (CDS). Several studies support the hypothesis that CDS can reverse levodopa‐induced motor complications. Other potential benefits of CDS include alleviating nocturnal disturbances, minimizing daytime sleepiness, avoiding priming for motor fluctuations and dyskinesia, preventing the development of gastrointestinal dysfunction and reducing the risk of developing psychosis or behavioural disturbances. Continuous infusion of dopaminergic therapies is impractical for the routine treatment of large numbers of patients. Although catechol‐O‐methyltransferase inhibitors or sustained‐release preparations of levodopa may be beneficial, they do not entirely eliminate pulsatile stimulation of dopamine receptors. A new dopamine agonist (rotigotine), delivered over 24 h by a once‐daily transdermal patch, has been investigated in several clinical trials. Continuous delivery of rotigotine has been shown to provide ‘true’ CDS in animal models. The potential of true CDS therapy to prevent or reduce long‐term motor and non‐motor complications requires investigation in appropriately designed clinical trials.</abstract><qualityIndicators><score>7.84</score><pdfVersion>1.4</pdfVersion><pdfPageSize>595.276 x 782.362 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1502</abstractCharCount><pdfWordCount>6437</pdfWordCount><pdfCharCount>44649</pdfCharCount><pdfPageCount>10</pdfPageCount><abstractWordCount>195</abstractWordCount></qualityIndicators><title>Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease</title><genre><json:string>review-article</json:string></genre><host><volume>15</volume><publisherId><json:string>ENE</json:string></publisherId><pages><total>10</total><last>15</last><first>6</first></pages><issn><json:string>1351-5101</json:string></issn><issue>1</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1468-1331</json:string></eissn><title>European Journal of Neurology</title><doi><json:string>10.1111/(ISSN)1468-1331</json:string></doi></host><publicationDate>2008</publicationDate><copyrightDate>2008</copyrightDate><doi><json:string>10.1111/j.1468-1331.2007.01674.x</json:string></doi><id>79DB4C9C3D025C0A3FD2EB3451F445BDF602CBEA</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/79DB4C9C3D025C0A3FD2EB3451F445BDF602CBEA/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/79DB4C9C3D025C0A3FD2EB3451F445BDF602CBEA/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/79DB4C9C3D025C0A3FD2EB3451F445BDF602CBEA/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>WILEY</p></availability><date>2008</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease</title><author><persName><forename type="first">M.</forename><surname>Steiger</surname></persName><affiliation>Walton Centre for Neurology and Neurosurgery, NHS Trust, Liverpool, UK</affiliation></author></analytic><monogr><title level="j">European Journal of Neurology</title><idno type="pISSN">1351-5101</idno><idno type="eISSN">1468-1331</idno><idno type="DOI">10.1111/(ISSN)1468-1331</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2008-01"></date><biblScope unit="volume">15</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="6">6</biblScope><biblScope unit="page" to="15">15</biblScope></imprint></monogr><idno type="istex">79DB4C9C3D025C0A3FD2EB3451F445BDF602CBEA</idno><idno type="DOI">10.1111/j.1468-1331.2007.01674.x</idno><idno type="ArticleID">ENE1674</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2008</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Current dopaminergic therapies for the treatment of Parkinson's disease are associated with the development of long‐term motor complications. Abnormal pulsatile stimulation of dopamine receptors is thought to underlie the development of motor complications. There is thus a need for therapies that mimic the normal physiological state more closely by resulting in constant dopaminergic stimulation (CDS). Several studies support the hypothesis that CDS can reverse levodopa‐induced motor complications. Other potential benefits of CDS include alleviating nocturnal disturbances, minimizing daytime sleepiness, avoiding priming for motor fluctuations and dyskinesia, preventing the development of gastrointestinal dysfunction and reducing the risk of developing psychosis or behavioural disturbances. Continuous infusion of dopaminergic therapies is impractical for the routine treatment of large numbers of patients. Although catechol‐O‐methyltransferase inhibitors or sustained‐release preparations of levodopa may be beneficial, they do not entirely eliminate pulsatile stimulation of dopamine receptors. A new dopamine agonist (rotigotine), delivered over 24 h by a once‐daily transdermal patch, has been investigated in several clinical trials. Continuous delivery of rotigotine has been shown to provide ‘true’ CDS in animal models. The potential of true CDS therapy to prevent or reduce long‐term motor and non‐motor complications requires investigation in appropriately designed clinical trials.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>constant dopaminergic stimulation</term></item><item><term>dopaminergic</term></item><item><term>Parkinson's disease</term></item><item><term>rotigotine</term></item><item><term>transdermal</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/79DB4C9C3D025C0A3FD2EB3451F445BDF602CBEA/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1468-1331</doi><issn type="print">1351-5101</issn><issn type="electronic">1468-1331</issn><idGroup><id type="product" value="ENE"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="EUROPEAN JOURNAL OF NEUROLOGY">European Journal of Neurology</title></titleGroup></publicationMeta><publicationMeta level="part" position="01001"><doi origin="wiley">10.1111/ene.2008.15.issue-1</doi><numberingGroup><numbering type="journalVolume" number="15">15</numbering><numbering type="journalIssue" number="1">1</numbering></numberingGroup><coverDate startDate="2008-01">January 2008</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="3" status="forIssue"><doi origin="wiley">10.1111/j.1468-1331.2007.01674.x</doi><idGroup><id type="unit" value="ENE1674"></id></idGroup><countGroup><count type="pageTotal" number="10"></count></countGroup><titleGroup><title type="tocHeading1">Review Article</title></titleGroup><eventGroup><event type="firstOnline" date="2007-11-27"></event><event type="publishedOnlineFinalForm" date="2007-11-27"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.5 mode:FullText source:FullText result:FullText" date="2010-04-07"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-24"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-16"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="6">6</numbering><numbering type="pageLast" number="15">15</numbering></numberingGroup><correspondenceTo>Malcolm Steiger, MD, Walton Centre for Neurology and Neurosurgery, Lower Lane, Liverpool L9 7LJ, UK (tel.: +44 151 529 5709; fax: +44 151 529 5512; e‐mail: <email>malcolm.steiger@thewaltoncentre.nhs.uk</email>)</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ENE.ENE1674.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Received 9 May 2006 Accepted 11 October 2006</unparsedEditorialHistory><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="2"></count></countGroup><titleGroup><title type="main">Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease</title><title type="shortAuthors">M. Steiger</title><title type="short">CDS and PD therapies</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#aff-1-1"><personName><givenNames>M.</givenNames><familyName>Steiger</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="aff-1-1" countryCode="GB"><unparsedAffiliation>Walton Centre for Neurology and Neurosurgery, NHS Trust, Liverpool, UK</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">constant dopaminergic stimulation</keyword><keyword xml:id="k2">dopaminergic</keyword><keyword xml:id="k3">Parkinson's disease</keyword><keyword xml:id="k4">rotigotine</keyword><keyword xml:id="k5">transdermal</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p>Current dopaminergic therapies for the treatment of Parkinson's disease are associated with the development of long‐term motor complications. Abnormal pulsatile stimulation of dopamine receptors is thought to underlie the development of motor complications. There is thus a need for therapies that mimic the normal physiological state more closely by resulting in constant dopaminergic stimulation (CDS). Several studies support the hypothesis that CDS can reverse levodopa‐induced motor complications. Other potential benefits of CDS include alleviating nocturnal disturbances, minimizing daytime sleepiness, avoiding priming for motor fluctuations and dyskinesia, preventing the development of gastrointestinal dysfunction and reducing the risk of developing psychosis or behavioural disturbances. Continuous infusion of dopaminergic therapies is impractical for the routine treatment of large numbers of patients. Although catechol‐<i>O</i>‐methyltransferase inhibitors or sustained‐release preparations of levodopa may be beneficial, they do not entirely eliminate pulsatile stimulation of dopamine receptors. A new dopamine agonist (rotigotine), delivered over 24 h by a once‐daily transdermal patch, has been investigated in several clinical trials. Continuous delivery of rotigotine has been shown to provide ‘true’ CDS in animal models. The potential of true CDS therapy to prevent or reduce long‐term motor and non‐motor complications requires investigation in appropriately designed clinical trials.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease</title></titleInfo><titleInfo type="abbreviated"><title>CDS and PD therapies</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Steiger</namePart><affiliation>Walton Centre for Neurology and Neurosurgery, NHS Trust, Liverpool, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2008-01</dateIssued><edition>Received 9 May 2006 Accepted 11 October 2006</edition><copyrightDate encoding="w3cdtf">2008</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">2</extent></physicalDescription><abstract lang="en">Current dopaminergic therapies for the treatment of Parkinson's disease are associated with the development of long‐term motor complications. Abnormal pulsatile stimulation of dopamine receptors is thought to underlie the development of motor complications. There is thus a need for therapies that mimic the normal physiological state more closely by resulting in constant dopaminergic stimulation (CDS). Several studies support the hypothesis that CDS can reverse levodopa‐induced motor complications. Other potential benefits of CDS include alleviating nocturnal disturbances, minimizing daytime sleepiness, avoiding priming for motor fluctuations and dyskinesia, preventing the development of gastrointestinal dysfunction and reducing the risk of developing psychosis or behavioural disturbances. Continuous infusion of dopaminergic therapies is impractical for the routine treatment of large numbers of patients. Although catechol‐O‐methyltransferase inhibitors or sustained‐release preparations of levodopa may be beneficial, they do not entirely eliminate pulsatile stimulation of dopamine receptors. A new dopamine agonist (rotigotine), delivered over 24 h by a once‐daily transdermal patch, has been investigated in several clinical trials. Continuous delivery of rotigotine has been shown to provide ‘true’ CDS in animal models. The potential of true CDS therapy to prevent or reduce long‐term motor and non‐motor complications requires investigation in appropriately designed clinical trials.</abstract><subject lang="en"><genre>Keywords</genre><topic>constant dopaminergic stimulation</topic><topic>dopaminergic</topic><topic>Parkinson's disease</topic><topic>rotigotine</topic><topic>transdermal</topic></subject><relatedItem type="host"><titleInfo><title>European Journal of Neurology</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">1351-5101</identifier><identifier type="eISSN">1468-1331</identifier><identifier type="DOI">10.1111/(ISSN)1468-1331</identifier><identifier type="PublisherID">ENE</identifier><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>6</start><end>15</end><total>10</total></extent></part></relatedItem><identifier type="istex">79DB4C9C3D025C0A3FD2EB3451F445BDF602CBEA</identifier><identifier type="DOI">10.1111/j.1468-1331.2007.01674.x</identifier><identifier type="ArticleID">ENE1674</identifier><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E85 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000E85 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:79DB4C9C3D025C0A3FD2EB3451F445BDF602CBEA
|texte= Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |